ACR CONVERGENCE 2020—New evidence, though derived from small numbers, suggest that treatment with the TNF-inhibitor certolizumab could help improve high-risk pregnancy outcomes in women with antiphospholipid syndrome (with or without systemic lupus erythematosus) and lupus anticoagulants, an expert said.
In the Phase 2 IMPACT trial, which has already enrolled 27 women and is continuing to enroll patients, pregnancies with data that could be evaluated had much lower numbers of fetal demise or preeclampsia than what had been expected based on a review of prior literature.
Jane Salmon, MD, professor of medicine and professor of medicine in obstetrics and gynecology at the Hospital for Special Surgery, New York, discussed this new line of research in this Rheumatology Research Foundation Memorial Lectureship session to honor Shaun Ruddy, MD.
See our full coverage of this session and other ACR Convergence 2020 sessions.
